Lite&Fog, a German agtech specializing in fogponics, and Bright Biotech, a UK company that has been cultivating tobacco plants, entered a partnership. The collaboration promises to address the cost-effective production of proteins, aiming to open doors to advancements in novel food production and regenerative medicine.

Combining Lite&Fog's Fogponics technology and Bright Biotech's molecular farming expertise creates a powerful platform for producing high-quality proteins at scale. Their efforts aim to achieve a daily production capacity based on up to 20 tons of tobacco plants - a milestone that could change the field of molecular farming.

Regenerative medicine
According to the companies, the collaboration holds great potential for novel food technologies and regenerative medicine, for example. Regenerative medicine, a healthcare approach that uses stem cells in treatments of very hard or impossible-to-treat cases, has emerged as a transformative force in modern medicine.

However, the production of proteins for these applications must adhere to stringent Good Manufacturing Practice (GMP) regulations. GMP is a set of quality standards for the manufacturing, testing, and control of pharmaceutical products to ensure their consistency, safety, and efficacy.

Adherence to GMP
Both companies are committed to upholding the GMP standards throughout the entire production process. This commitment encompasses the sourcing of raw materials, the cultivation and processing of tobacco plants, the extraction and purification of proteins, and the final packaging and labeling of products.

For more information:
Martin Peter, Co-Founder and CEO
Lite+Fog GmbH
Schwarze-Pumpe-Weg 16
12681 Berlin
martin.peter@liteandfog.com
www.liteandfog.com

Bright Biotech
www.brightbiotech.co.uk